Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases

Experimental and Molecular Medicine

Volumn 47, Issue 3, 2015, Pages

  Choi, Un Yung ^a   Kang, Ji Seon ^a   Hwang, Yune Sahng ^a   Kim, Young Joon ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2-5A-DEPENDENT RIBONUCLEASE; BIOLOGICAL MARKER; OAS1 PROTEIN, HUMAN; OAS3 PROTEIN, HUMAN; RIBONUCLEASE;

ANIMAL; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MULTIGENE FAMILY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; BIOMARKERS; DISEASE SUSCEPTIBILITY; ENDORIBONUCLEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION;

EID: 84961529059     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2014.110     Document Type: Review

References (58)

1. Hovanessian AG, Wood JN. Anticellular and antiviral effects of pppA (2'p5'A)n. Virology 1980; 101: 81–90.
2. Chebath J, Benech P, Revel M, Vigneron M. Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. Nature 1987; 330: 587–588.
3. Schroder HC, Suhadolnik RJ, Pfleiderer W, Charubala R, Muller WE. 2'-5') Oligoadenylate and intracellular immunity against retrovirus infection. Int J Biochem 1992; 24: 55–63.
4. Kristiansen H, Scherer CA, McVean M, Iadonato SP, Vends S, Thavachelvam K et al. Extracellular 2'-5' oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J Virol 2010; 84: 11898–11904.
5. Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Guenet JL, Lucas M, Despres P. The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J Biol Chem 2006; 281: 4624–4637.
6. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559–568.
7. Hovnanian A, Rebouillat D, Mattei MG, Levy ER, Marie I, Monaco AP et al. The human 2',5'-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Genomics 1998; 52: 267–277.
8. Bonnevie-Nielsen V, Field LL, Lu S, Zheng DJ, Li M, Martensen PM et al. Variation in antiviral 2',5'-oligoadenylate synthetase (2' 5' AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005; 76: 623–633.
9. Guo X, Li X, Xu Y, Sun T, Yang G, Wu Z et al. Identification of OASL d, a splice variant of human OASL, with antiviral activity. Int J Biochem Cell Biol 2012; 44: 1133–1138.
10. Eskildsen S, Hartmann R, Kjeldgaard NO, Justesen J. Gene structure of the murine 2'-5'-oligoadenylate synthetase family. Cell Mol Life Sci 2002; 59: 1212–1222.
11. Eskildsen S, Justesen J, Schierup MH, Hartmann R. Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family. Nucleic Acids Res 2003; 31: 3166–3173.
12. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011; 31: 49–57.
13. Ghosh A, Sarkar SN, Guo WD, Bandyopadhyay S, Sen GC. Enzymatic activity of 2'-5'-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization of the protein. J Biol Chem 1997; 272: 33220–33226.
14. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF et al. Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J Biol Chem 1994; 269: 14153–14158.
15. Courtney SC, Di H, Stockman BM, Liu H, Scherbik SV, Brinton MA. Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice. J Virol 2012; 86: 7953–7963.
16. Lin RJ, Yu HP, Chang BL, Tang WC, Liao CL, Lin YL. Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection. J Immunol 2009; 183: 8035–8043.
17. Ibsen MS, Gad HH, Thavachelvam K, Boesen T, Despres P, Hartmann R. The 2'-5' oligoadenylate synthetase 3 (OAS3) enzyme potently synthesizes the 2'-5' oligoadenylates required for RNase L activation. J Virol 2014; 88: 14222–14231.
18. Kwon YC, Kang JI, Hwang SB, Ahn BY. The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus. FEBS Lett 2013; 587: 156–164.
19. Rebouillat D, Hovanessian AG. The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res 1999; 19: 295–308.
20. Bordignon J, Probst CM, Mosimann AL, Pavoni DP, Stella V, Buck GA et al. Expression profile of interferon stimulated genes in central nervous system of mice infected with dengue virus Type-1. Virology 2008; 377: 319–329.
21. Warke RV, Xhaja K, Martin KJ, Fournier MF, Shaw SK, Brizuela N et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virol 2003; 77: 11822–11832.
22. Alagarasu K, Honap T, Damle IM, Mulay AP, Shah PS, Cecilia D. Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection. Infect Genet Evol 2013; 14: 390–395.
23. Brehin AC, Casademont I, Frenkiel MP, Julier C, Sakuntabhai A, Despres P. The large form of human 2',5'-oligoadenylate synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 2009; 384: 216–222.
24. Henrik Gad H, Paulous S, Belarbi E, Diancourt L, Drosten C, Kummerer BM et al. The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology 2012; 434: 27–37.
25. Priya R, Patro IK, Parida MM. TLR3 mediated innate immune response in mice brain following infection with Chikungunya virus. Virus Res 2014; 189: 194–205.
26. Hovnanian A, Rebouillat D, Levy ER, Mattei MG, Hovanessian AG. The human 2',5'-oligoadenylate synthetase-like gene (OASL) encoding the interferon-induced 56-kDa protein maps to chromosome 12q24.2 in the proximity of the 2',5'-OAS locus. Genomics 1999; 56: 362–363.
27. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR et al. Differential regulation of the OASL and OAS1 genes in response to viral infections. J Interferon Cytokine Res 2009; 29: 199–207.
28. Eskildsen S, Justesen J, Schierup MH, Hartmann R. Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family. Nucleic Acids Res 2003; 31: 3166–3173.
29. Rogozin IB, Aravind L, Koonin EV. Differential action of natural selection on the N and C-terminal domains of 2'-5' oligoadenylate synthetases and the potential nuclease function of the C-terminal domain. J Mol Biol 2003; 326: 1449–1461.
30. Harcourt JL, Hagan MK, Offermann MK. Modulation of double-stranded RNA-mediated gene induction by interferon in human umbilical vein endothelial cells. J Interferon Cytokine Res 2000; 20: 1007–1013.
31. Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008; 49: 184–191.
32. Marques J, Anwar J, Eskildsen-Larsen S, Rebouillat D, Paludan SR, Sen G et al. The p59 oligoadenylate synthetase-like protein possesses antiviral activity that requires the C-terminal ubiquitin-like domain. J Gen Virol 2008; 89: 2767–2772.
33. Zhu J, Zhang Y, Ghosh A, Cuevas RA, Forero A, Dhar J et al. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 2014; 40: 936–948.
34. Lee MS, Kim B, Oh GT, Kim YJ. OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat Immunol 2013; 14: 346–355.
35. Kim YM, Choi WY, Oh CM, Han GH, Kim YJ. Secondary structure of the Irf7 5'-UTR, analyzed using SHAPE (selective 2'-hydroxyl acylation analyzed by primer extension). BMB Rep 2014; 47: 558–562.
36. Lee MS, Park CH, Jeong YH, Kim YJ, Ha SJ. Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion. PLoS Pathog 2013; 9: e1003478.
37. Almeida GMD, de Oliveira DB, Botelho LM, Silva LKD, Guedes ACM, Santos FPST et al. Differential upregulation of human 2' 5' OAS genes on systemic sclerosis: detection of increased basal levels of OASL and OAS2 genes through a qPCR based assay. Autoimmunity 2014; 47: 119–126.
38. Croze E. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J Interferon Cytokine Res 2010; 30: 743–749.
39. Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston MI. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983; 157: 2140–2146.
40. Hertzog PJ, Emery P, Cheetham BF, Mackay IR, Linnane AW. Interferons in rheumatoid arthritis: alterations in production and response related to disease activity. Clin Immunol Immunopathol 1988; 48: 192–201.
41. Ye S, Guo Q, Tang JP, Yang CD, Shen N, Chen SL. Could 2' 5'-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study. Clin Rheumatol 2007; 26: 186–190.
42. Zhou Y, Kang MJ, Jha BK, Silverman RH, Lee CG, Elias JA. Role of ribonuclease L in viral pathogen-associated molecular pattern/influenza virus and cigarette smoke-induced inflammation and remodeling. J Immunol 2013; 191: 2637–2646.
43. Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol 2014; 66: 1421–1431.
44. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358: 261–264.
45. Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, Gibbs RA et al. Single nucleotide polymorphisms in genes for 2'-5'-Oligoadenylate synthe-tase and RNase L in patients hospitalized with West Nile virus infection. J Infect Dis 2005; 192: 1741–1748.
46. Middelberg RPS, Ferreira MAR, Henders AK, Heath AC, Madden PAF, Montgomery GW et al. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med Genet 2011; 12: 123.
47. Domingo-Gil E, Esteban M. Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved. Apoptosis 2006; 11: 725–738.
48. Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL et al. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 1998; 5: 313–320.
49. Latham KE, Cosenza S, Reichenbach NL, Mordechai E, Adelson ME, Kon N et al. Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative. Oncogene 1996; 12: 827–837.
50. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007; 67: 3845–3852.
51. Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG et al. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-gamma-mediated apoptosis. Oncogene 2005; 24: 5492–5501.
52. Andersen JB, Strandbygard DJ, Hartmann R, Justesen J. Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. Eur J Biochem 2004; 271: 628–636.
53. Sperling J, Chebath J, Araddann H, Offen D, Spann P, Lehrer R et al. Possible involvement of (2'-5')oligoadenylate synthetase-activity in pre-messenger-RNA splicing. Proc Natl Acad Sci USA 1991; 88: 10377–10381.
54. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411–419.
55. Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS ONE 2010; 5: e8667.
56. He J, Feng D, de Vlas SJ, Wang H, Fontanet A, Zhang P et al. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis 2006; 6: 106.
57. Tessier MC, Qu HQ, Frechette R, Bacot F, Grabs R, Taback SP et al. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet 2006; 43: 129–132.
58. Barkhash AV, Perelygin AA, Babenko VN, Myasnikova NG, Pilipenko PI, Romaschenko AG et al. Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. J Infect Dis 2010; 202: 1813–1818.